Correlation between fine motor activity and striatal dopamine D2 receptor density in patients with schizophrenia and healthy controls.
Striatal dopamine D2 receptor density is an important indicator of many neuropsychiatric disorders and also of motor activity. This study examined the relationship between a fine motor task (finger tapping test, FTT) and striatal D2 dopamine receptor density by examining 20 healthy volunteers and 20 schizophrenic patients. Striatal D2 receptor density was determined with single photon emission computed tomography using [123I]IBZM (iodo-benzamide). The correlation between the FTT score and striatal D2 receptor density was statistically significant not only in the patient group but also in healthy controls. The FTT scores and striatal D2 receptor density were lower in medicated patients than that in healthy controls. Compared with the Simpson-Angus Scale scores, the FTT scores were more strongly associated with striatal D2 receptor density. The use of neuroleptic medication seemed to influence the associations between FTT scores and striatal D2 receptor density in the patient group. The FTT scores and striatal D2 receptor density were age-sensitive in healthy controls. FTT may be a more sensitive tool for detecting neuroleptic-induced motor impairment in patients with schizophrenia. The sensitivity of the FTT to age and neuroleptic effects may be explained in part by a decline in dopamine D2 density.
Yang
Yen Kuang
YK
Department of Psychiatry, College of Medicine, National Cheng Kung University and University Hospital, 138 Sheng Li Road, Tainan 70428, Taiwan, ROC.
Chiu
Nan Tsing
NT
Chen
Chwen Cheng
CC
Chen
Mitchell
M
Yeh
Tzung Lieh
TL
Lee
I Hui
IH
D000293:Adolescent; D000328:Adult; D001549:Benzamides / Q000493:pharmacokinetics; D002452:Cell Count; D003287:Contrast Media; D003342:Corpus Striatum / Q000378:metabolism* / Q000503:physiopathology*; D039721:Diagnostic and Statistical Manual of Mental Disorders; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D011597:Psychomotor Performance / Q000502:physiology*; D011759:Pyrrolidines / Q000493:pharmacokinetics; D017448:Receptors, Dopamine D2 / Q000378:metabolism*; D012559:Schizophrenia / Q000175:diagnosis / Q000378:metabolism* / Q000503:physiopathology*; D015899:Tomography, Emission-Computed, Single-Photon
D001549:Benzamides; D003287:Contrast Media; D011759:Pyrrolidines; D017448:Receptors, Dopamine D2; C055743:3-iodo-2-hydroxy-6-methoxy-N-((1-ethyl-2-pyrrolidinyl)methyl)benzamide